Oruka Therapeutics (ORKA) Retained Earnings (2010 - 2026)
Oruka Therapeutics (ORKA) recorded quarterly Retained Earnings of -$480000.0 in Q1 2026, up 99.75% quarter-over-quarter from -$189.2 million in Q4 2025, and down 7900.0% on a YoY basis from $6153.8 in Q1 2025.
Oruka Therapeutics (ORKA) Retained Earnings (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$480000.0 for Q1 2026.
- In Q1 2026, Retained Earnings fell 7900.0% year-over-year to -$480000.0; the TTM figure through Mar 2026 stood at -$480000.0 (down 7900.0% YoY), while the FY2025 annual figure was -$189.2 million, down 125.93% from the prior year.
- Retained Earnings was -$480000.0 for Q1 2026 at Oruka Therapeutics, up from -$189.2 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$6000.0 in Q1 2025 to a low of -$193.4 million in Q2 2024.
- Historically, Retained Earnings has averaged -$137.9 million across 5 years, with a median of -$182.2 million in 2022.
- The sharpest annual moves came in 2025 and 2026: Retained Earnings soared 100.0% in 2025, then sank 7900.0% in 2026.
- A 5-year view of Retained Earnings shows it stood at -$183.4 million in 2022, then retreated by 2.91% to -$188.7 million in 2023, then soared by 55.64% to -$83.7 million in 2024, then sank by 125.93% to -$189.2 million in 2025, then soared by 99.75% to -$480000.0 in 2026.
- The last three Retained Earnings figures came in at -$480000.0 (Q1 2026), -$189.2 million (Q4 2025), and -$159.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Oruka Therapeutics | 4.04 Bn | 3.65 Bn | - | -480,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -480,000.00 |
| Dec 31, 2025 | -189.16 Mn |
| Sep 30, 2025 | -159.57 Mn |
| Jun 30, 2025 | -27,000.00 |
| Mar 31, 2025 | -6,000.00 |
| Dec 31, 2024 | -83.72 Mn |
| Sep 30, 2024 | -57.94 Mn |
| Jun 30, 2024 | -193.43 Mn |
| Mar 31, 2024 | -190.75 Mn |
| Dec 31, 2023 | -188.74 Mn |
| Sep 30, 2023 | -187.65 Mn |
| Jun 30, 2023 | -186.23 Mn |
| Mar 31, 2023 | -184.75 Mn |
| Dec 31, 2022 | -183.40 Mn |
| Sep 30, 2022 | -182.23 Mn |
| Jun 30, 2022 | -179.90 Mn |
| Mar 31, 2022 | -176.75 Mn |
| Dec 31, 2021 | -173.48 Mn |
| Sep 30, 2021 | -167.80 Mn |
| Jun 30, 2021 | -163.09 Mn |